Iterum Therapeutics plc
ITRM
$0.99
-$0.007-0.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 342.00K | 254.00K | -- | -- | -- |
| Gross Profit | -342.00K | -254.00K | -- | -- | -- |
| SG&A Expenses | 2.78M | 2.12M | 1.78M | 1.90M | 2.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.71M | 3.67M | 4.89M | 3.98M | 6.16M |
| Operating Income | -3.71M | -3.67M | -4.89M | -3.98M | -6.16M |
| Income Before Tax | -4.83M | -6.56M | -5.96M | -4.97M | -7.05M |
| Income Tax Expenses | 60.00K | 25.00K | 136.00K | 31.00K | 48.00K |
| Earnings from Continuing Operations | -4.89M | -6.58M | -6.09M | -5.00M | -7.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.89M | -6.58M | -6.09M | -5.00M | -7.10M |
| EBIT | -3.71M | -3.67M | -4.89M | -3.98M | -6.16M |
| EBITDA | -3.36M | -3.41M | -4.88M | -3.97M | -6.16M |
| EPS Basic | -0.14 | -0.25 | -0.30 | -0.30 | -0.46 |
| Normalized Basic EPS | -0.09 | -0.15 | -0.19 | -0.19 | -0.29 |
| EPS Diluted | -0.14 | -0.25 | -0.30 | -0.30 | -0.46 |
| Normalized Diluted EPS | -0.09 | -0.15 | -0.19 | -0.19 | -0.29 |
| Average Basic Shares Outstanding | 34.06M | 26.69M | 20.04M | 16.55M | 15.43M |
| Average Diluted Shares Outstanding | 34.06M | 26.69M | 20.04M | 16.55M | 15.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |